

Immune activation in chronic heart failure and the role of endotoxin

| | | |
|--|---|---|
| Submission date 29/09/2006 | Recruitment status No longer recruiting | <input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol |
| Registration date 29/09/2006 | Overall study status Completed | <input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results |
| Last Edited 28/02/2020 | Condition category Circulatory System | <input type="checkbox"/> Individual participant data |

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Philip A Poole-Wilson

Contact details
Imperial College School of Medicine NHLI
Guy Scadding Building
Dovehouse Street
London
United Kingdom
SW3 6LY

Additional identifiers

Protocol serial number
N0201082084

Study information

Scientific Title
Immune activation in chronic heart failure and the role of endotoxin

Study objectives

To investigate whether CHF is associated with immune dysregulation and to establish whether endotoxin levels are increased in heart failure patients and whether an endotoxin challenge is a component of immune activation in patients with severe CHF. Study could lead to new therapeutic insights and could contribute to the development of new therapeutic strategies for immune activation in CHF and a syndrome currently without effective treatment ie cardiac cachexia.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Cardiovascular: Chronic heart failure

Interventions

Study A: Randomised Controlled Trial (10 cachectic and 10 non-cachectic stable CHF patients, and 10 controls)

Study B: Cohort Observation (10 CHF patients presenting acute oedematous exacerbation)

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s)

Not provided at time of registration

Completion date

29/06/2006

Eligibility**Key inclusion criteria**

Not provided at time of registration

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/04/1997

Date of final enrolment

29/06/2006

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

Imperial College School of Medicine NHLI

London

United Kingdom

SW3 6LY

Sponsor information**Organisation**

Record Provided by the NHSTCT Register - 2006 Update - Department of Health

Funder(s)**Funder type**

Government

Funder Name

Royal Brompton and Harefield NHS Trust (UK) Joint Committee for Research

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---------------------------------|---------|--------------|------------|----------------|-----------------|
| Results article | results | 29/05/1999 | 28/02/2020 | Yes | No |